

Ref: GLL/OC/2019-20/0039

Date: 14/11/2019.

To
Dy. General Manager,
BSE Ltd.,
Phiroje Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To
Asst. Manager (Listing)
The Ahmedabad Stock Exchange Ltd.,
Kamdhenu Complex, Opp.Sahajanand College,
Ahmedabad – 380 015.

To
The Secretary
The Calcutta Stock Exchange Association Ltd.,
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject : Submission of Standalone and Consolidated Un-Audited Limited Reviewed Financial Result as per Ind-As for the 2nd Quarter and Half Year Ended 30th September, 2019.
Reference : Security ID : GENNEX & Script Code – 531739


We enclose the Standalone and Consolidated Un-Audited Financial Results as per Ind-AS for the 2nd Quarter and Half Year ended 30th September, 2019 of the Company together with Limited Review Report thereon pursuant to the Regulation 33(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 which was approved and taken on records by the Board of Directors at its Meeting held today i.e., 14.11.2019.

The Board Meeting commenced at 04:30 p.m. and concluded at 06:00 p.m.

We would be obliged if you could take the above on records.

Thanking You,

Yours faithfully,
For Gennex Laboratories Ltd.,



Authorised Signatory



Encl: as above

Gennex Laboratories Limited



GENNEX LABORATORIES LIMITED

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2019

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN: L24230TG1990PLC011168

(All amounts in Rs.lakhs except EPES and Ratios)							
Statement of standalone Unaudited Financial Results for the Quarter and Six months ended September 30,2019							(Rs. in lakhs)
Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year ended
		30.09.2019 (Unaudited)	30.06.2019 (Unaudited)	30.09.2018 (Unaudited)	30.09.2019 (Unaudited)	30.09.2018 (Unaudited)	31.03.2019 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	1339.60	1608.73	1078.16	2948.33	2022.65	5580.27
	(b) Other operating Income	20.24	34.18	18.27	54.42	32.70	78.25
	Total Income from operations (net)	1359.84	1642.91	1096.43	3002.75	2055.35	5658.52
2	Expenses						
	(a) Cost of material consumed	832.33	1030.07	696.09	1862.40	1315.07	3468.05
	(b) Purchases of stock-in-trade	0.00	0.00	2.93	0.00	2.93	40.52
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-62.02	-97.55	-88.53	-159.57	-185.70	-238.82
	(d) Employee benefit expense	163.21	170.13	135.40	333.34	263.49	612.20
	(e) Finance Cost	17.65	25.42	16.45	43.07	33.44	98.47
	(f) Depreciation and amortisation expense	28.04	22.92	24.48	50.96	48.50	79.38
	(g) Other expenses	316.69	385.18	261.46	701.87	482.10	1296.00
	Total expenses	1295.9	1536.17	1048.28	2832.07	1959.83	5355.80
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	63.94	106.74	48.15	170.68	95.52	302.72
4	Exceptional items	10.86	0	0.00	10.86	0.00	-
5	Profit(+)/Loss(-) before tax (3+4)	74.80	106.74	48.15	181.54	95.52	302.72
6	Tax Expenses for earlier years						-0.15
7	Current Tax	-19.00	-27.00		-46.00		-85.00
8	Deferred tax						4.51
9	Total Tax expense	-19.00	-27.00	0.00	-46.00	0.00	-80.64
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	0	0	0	0
11	Net Profit for the period from continuing operation (5-9)	55.80	79.74	48.15	135.54	95.52	222.08
12	Profit(+)/Loss(-) from discontinued operations before tax	0.0	0.0	0.0	0.0	0.0	0.0
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	55.80	79.74	48.15	135.54	95.52	222.08
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	Net profit(loss) for period	55.80	79.74	48.15	135.54	95.52	222.08
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
	Other Equity						2134.74
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.044	0.063	0.038	0.107	0.076	0.176
	(b) Diluted	0.044	0.063	0.038	0.107	0.076	0.176

Statement of Assets and Liabilities			(Rs. in lakhs)
Particulars	As at September 30,2019		As at March 31,2019
	Unaudited		Audited
B) ASSETS			
1 Non-Current Assets			
a) Tangible Assets	1538.19		1563.81
b) Intangible Assets	0.00		0.00
c) Non-Current Investments	701.00		701.00
d) Long-term loans and advances	22.74		22.24
Sub-total Non-current assets	2261.93		2287.05
2 Current Assets			
a) Current Investments	0.00		0.00
b) Inventories	823.11		532.71
c) Trade receivable	855.36		1039.77
d) Cash and Cash equivalents	68.64		314.65
e) Short-term loans and advances	1482.48		1014.32
f) Other current assets	1.81		2.79
Sub-total - Current assets	3231.40		2904.24
TOTAL - ASSETS	5493.33		5191.29
A) EQUITY AND LIABILITIES			
1 Shareholders' Funds:			
a) Share Capital	1265.03		1265.03
b) Reserves and Surplus	2270.28		2134.74
Sub-total Shareholders' Fund	3535.31		3399.77
2 Non - Current Liabilities			
a) Long-term borrowings	0.00		0.00
b) Other non current liabilities	61.51		61.50
c) Long-term provisions	0.00		0.00
Sub-total Non-current liabilities	61.51		61.50
3 Current Liabilities			
a) Short-term borrowings	449.09		453.87
b) Trade payables	907.67		815.43
c) Other current liabilities	348.11		315.08
d) Short-term provisions	191.64		145.64
Sub-total Current liabilities	1896.51		1730.02
TOTAL EQUITY AND LIABILITIES	5493.33		5191.29

Notes to the results:

- The above audited financial results have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on Nov 14, 2019.
- The statement has been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of Companies Act, 2013 and other prescribed accounting practices and policies to the extent possible.
- The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely " Bulk Drugs,Biotech Products and Intermediates".
- Provision for IAS-12 Deferred Tax will be made at the end of the year.
- Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- The Figures for the Quarter ended 31-March-2019 and the corresponding quarter ended in the Previous year, as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to data figures upto the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit. Previously period/year figures have

For and on behalf of the Board
For Gennex Laboratories Limited
sd/-
Arihant Baid
Managing Director

Place: Hyderabad
Date: 14.11.2019



	30-09-2019	31-03-2019
	(Rs. In Lacs)	(Rs. In Lacs)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax	135.54	302.72
Adjustment for :		
Depreciation and amoratisation expense	50.96	98.47
Finance Cost	43.07	79.38
Interest Income	-1.97	-4.72
(Gain)/loss on sale of asset	0	0
Operating Profit before working capital changes	227.60	475.85
Adjustment for :		
Trade payables and other liability	124.61	-327.92
Trade receivables	184.41	6.14
Inventories	-290.40	-298.85
Financial and other Assets	-467.17	367.48
Cash generated from operations	-220.95	222.70
Adjustments for :		
Income Taxes paid	0.00	-35.15
Net Cash from operating activities	-220.95	187.55
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property,plant and equipment	-25.34	-104.15
Sale of property,plant and equipment	0.00	0.00
Interest Income	1.97	4.72
Net Cash used in Investing activities	-23.37	-99.43
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Borrowings	0.00	0.00
Changes in Long Term Borrowings	0	-37.63
Changes in Short Term Borrowings (Net)	-4.78	241.71
Interest Paid	-38.29	-79.38
Net Cash from Financing activities	-43.07	124.70
Net Increase / (Decrease) in Cash and Cash equivalent (A+B+C)	-287.40	212.82
Cash and Cash Equivalents as at the beginning of the year	314.65	101.83
Cash and Cash Equivalents as at the end of the year	27.25	314.65

Notes:

1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind-AS)- 7 on Statement of Cash Flow.
2. Figures in bracket indicate cash outflow.
3. Previous year comparatives have been reclassified to confirm with current year's presentation, wherever applicable.

**INDEPENDENT AUDITOR'S REVIEW REPORT ON
REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS**

To
The Board of Directors,
GENNEX LABORATORIES LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **GENNEX LABORATORIES LIMITED** ("the Company") for the Quarter and Six Months Ended 30th September, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement

For PPKG & CO
Chartered Accountants
FRN No. 009655S

Girdhari Lal Toshniwal
GIRDHARI LAL TOSHIWAL
(Partner)

M. No. 205140



Place : Hyderabad

Date : 14th November, 2019

UDIN: 19205140AA AAKY2509



GENNEX LABORATORIES LIMITED

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2019

Tel. No. +91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN: L24230TG1990PLC011168

(All amounts in Rs.lakhs except EPES and Ratios)							
Statement of Consolidated Unaudited Financial Results for the Quarter and Six months ended September 30,2018						(Rs. in lakhs)	
Sl. No.	Particulars	Quarter Ended			Half Year Ended		
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from Operations	1339.60	1608.73	1078.16	2948.33	2022.65	5580.27
	(b) Other operating Income	20.24	34.18	18.27	54.42	32.70	78.25
	Total Income from operations (net)	1359.84	1642.91	1096.43	3002.75	2055.35	5658.52
2	Expenses						
	(a) Cost of material consumed	832.33	1030.07	696.09	1862.40	1315.07	3468.05
	(b) Purchases of stock-in-trade	0.00	0.00	2.93	0.00	2.93	40.52
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-62.02	-97.55	-88.53	-159.57	-185.70	-238.82
	(d) Employee benefit expense	163.21	170.13	135.40	333.34	263.49	612.20
	(e) Finance Cost	17.65	25.42	16.45	43.07	33.44	98.47
	(f) Depreciation and amortisation expense	28.04	22.92	24.48	50.96	48.50	79.38
	(g) Other expenses	316.69	385.18	261.46	701.87	482.10	1296.00
	Total expenses	1295.9	1536.17	1048.28	2832.07	1959.83	5355.80
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	63.94	106.74	48.15	170.68	95.52	302.72
4	Exceptional items	10.86	0	0.00	10.86	0.00	-
5	Profit(+)/Loss(-) before tax (3+4)	74.80	106.74	48.15	181.54	95.52	302.72
6	Tax Expenses for earlier years						-0.15
7	Current Tax	-19.00	-27.00		-46.00		-85.00
8	Deferred tax						4.51
9	Total Tax expense	-19.00	-27.00	0.00	-46.00	0.00	-80.64
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	0	0	0	0
11	Net Profit for the period from continuing operation (5-9)	55.80	79.74	48.15	135.54	95.52	222.08
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	-2.94	-0.84	0.0	0.0	(2.94)	-8.08
16	Total profit(loss) for period	52.86	78.90	48.15	135.54	92.58	214.00
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	Net profit(loss) for period	52.86	78.90	48.15	135.54	92.58	214.00
19	Paid-up Equity Share Capital						
	(Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
	Other Equity						2134.74
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.042	0.062	0.038	0.107	0.073	0.169
	(b) Diluted	0.042	0.062	0.038	0.107	0.073	0.169

Statement of Assets and Liabilities			(Rs. in lakhs)
Particulars	As at September		As at March
	30,2019		31,2019
	Unaudited		Audited
B) ASSETS			
1 Non-Current Assets			
a) Tangible Assets	1538.19		1563.81
b) Intangible Assets	0.00		0.00
c) Non-Current Investments	698.06		691.98
d) Long-term loans and advances	22.74		22.24
Sub-total Non-current assets	2258.99		2278.03
2 Current Assets			
a) Current Investments	0.00		0.00
b) Inventories	823.11		532.71
c) Trade receivable	855.36		1039.77
d) Cash and Cash equivalents	68.64		314.65
e) Short-term loans and advances	1482.48		1014.32
f) Other current assets	1.81		2.79
Sub-total - Current assets	3231.40		2904.24
TOTAL - ASSETS	5490.39		5182.27
A) EQUITY AND LIABILITIES			
1 Shareholders' Funds:			
a) Share Capital	1265.03		1265.03
b) Reserves and Surplus	2267.34		2125.72
Sub-total Shareholders' Fund	3532.37		3390.75
2 Non - Current Liabilities			
a) Long-term borrowings	0.00		0.00
b) Other non current liabilities	61.51		61.50
c) Long-term provisions	0.00		0.00
Sub-total Non-current liabilities	61.51		61.50
3 Current Liabilities			
a) Short-term borrowings	449.09		453.87
b) Trade payables	907.67		815.43
c) Other current liabilities	348.11		315.08
d) Short-term provisions	191.64		145.64
Sub-total Current liabilities	1896.51		1730.02
TOTAL EQUITY AND LIABILITIES	5490.39		5182.27

Notes to the results:

- 1) The above audited financial results have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on Nov 14, 2019.
- 2) The statement has been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of Companies Act, 2013 and other prescribed accounting practices and policies to the extent possible.
- 3) The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely " Bulk Drugs,Biotech Products and Intermediates".
- 4) Provision for IAS-12 Deferred Tax will be made at the end of the year.
- 5) Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- 6) The Figures for the Quarter ended 31-March-2019 and the corresponding quarter ended in the Previous year, as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to data figures upto the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit. Previously period/year figures have

Place: Hyderabad
Date: 14.11.2019

For and on behalf of the Board
For Gennex Laboratories Limited
sd/-
Arihant Baid
Managing Director



	30-09-2019	31-03-2019
	(Rs. In Lacs)	(Rs. In Lacs)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax	135.54	302.72
Adjustment for :		
Depreciation and amoratisation expense	50.96	98.47
Finance Cost	43.07	79.38
Interest Income	-1.97	-4.72
(Gain)/loss on sale of asset	0	0
Operating Profit before working capital changes	227.60	475.85
Adjustment for :		
Trade payables and other liability	124.61	-327.92
Trade receivables	184.41	6.14
Inventories	-290.40	-298.85
Financial and other Assets	-467.17	367.48
Cash generated from operations	-220.95	222.70
Adjustments for :		
Income Taxes paid	0.00	-35.15
Net Cash from operating activities	-220.95	187.55
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property,plant and equipment	-25.34	-104.15
Sale of property,plant and equipment	0.00	0.00
Interest Income	1.97	4.72
Net Cash used in Investing activities	-23.37	-99.43
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Borrowings	0.00	0.00
Changes in Long Term Borrowings	0	-37.63
Changes in Short Term Borrowings (Net)	-4.78	241.71
Interest Paid	-38.29	-79.38
Net Cash from Financing activities	-43.07	124.70
Net Increase / (Decrease) in Cash and Cash equivalent (A+B+C)	-287.40	212.82
Cash and Cash Equivalents as at the beginning of the year	314.65	101.83
Cash and Cash Equivalents as at the end of the year	27.25	314.65

Notes:

1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind-AS)- 7 on Statement of Cash Flow.
2. Figures in bracket indicate cash outflow.
3. Previous year comparatives have been reclassified to confirm with current year's presentation, wherever applicable.

**INDEPENDENT AUDITOR'S REVIEW REPORT ON
REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

To
The Board of Directors,
GENNEX LABORATORIES LIMITED


We have reviewed the accompanying statement of Consolidated unaudited financial results of **GENNEX LABORATORIES LIMITED** ("the Company") for the Quarter and Six Months Ended 30th September, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement

For PPKG & CO
Chartered Accountants
FRN No. 009655S


GIRDHARI LAL TOSHNIWAL
(Partner)
M. No. 205140



Place : Hyderabad
Date : 14th November, 2019
UDIN : 19205140AAAAKZ6434